Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity

Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors Poster presentation today during AACR Annual Meeting 2019 ...
March 26, 2019 09:00 ET | Source: Biodesix, Inc.

Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR

BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...
March 18, 2019 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019

NEW HAVEN, Conn., March 18, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...